Literature DB >> 29063294

Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.

Nobuaki Matsubara1, Hirofumi Mukai2, Ako Hosono2, Mai Onomura2, Masaoki Sasaki2, Yoko Yajima3, Kensei Hashizume4, Masanobu Yasuda5, Miho Uemura4, Christian Zurth6.   

Abstract

Entities:  

Year:  2017        PMID： 29063294      PMCID： PMC6828099          DOI： 10.1007/s00280-017-3433-3

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  14 in total

Review 1.  Castration-resistant prostate cancer: from new pathophysiology to new treatment.

Authors:  Srikala S Sridhar; Stephen J Freedland; Martin E Gleave; Celestia Higano; Peter Mulders; Chris Parker; Oliver Sartor; Fred Saad
Journal:  Eur Urol       Date:  2013-08-11       Impact factor: 20.096

Review 2.  New agents for prostate cancer.

Authors:  N Agarwal; G Di Lorenzo; G Sonpavde; J Bellmunt
Journal:  Ann Oncol       Date:  2014-03-20       Impact factor: 32.976

3.  Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.

Authors:  Megumi Hori; Tomohiro Matsuda; Akiko Shibata; Kota Katanoda; Tomotaka Sobue; Hiroshi Nishimoto
Journal:  Jpn J Clin Oncol       Date:  2015-07-03       Impact factor: 3.019

4.  Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.

Authors:  Christophe Massard; Heidi M Penttinen; Egils Vjaters; Petri Bono; Vilnis Lietuvietis; Teuvo L Tammela; Annamari Vuorela; Pirjo Nykänen; Pasi Pohjanjousi; Amir Snapir; Karim Fizazi
Journal:  Eur Urol       Date:  2015-10-17       Impact factor: 20.096

Review 5.  Characterising the castration-resistant prostate cancer population: a systematic review.

Authors:  M Kirby; C Hirst; E D Crawford
Journal:  Int J Clin Pract       Date:  2011-11       Impact factor: 2.503

6.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

8.  Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.

Authors:  R Leibowitz-Amit; A M Joshua
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

Review 9.  Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.

Authors:  Álvaro Pinto
Journal:  Cancer Biol Ther       Date:  2013-11-01       Impact factor: 4.742

10.  Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.

Authors:  Anu-Maarit Moilanen; Reetta Riikonen; Riikka Oksala; Laura Ravanti; Eija Aho; Gerd Wohlfahrt; Pirjo S Nykänen; Olli P Törmäkangas; Jorma J Palvimo; Pekka J Kallio
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.